AbbVie announced a new round of 85 layoffs tied to its Irvine, California site within its eye-care business, effective July 20. The WARN notice continues a pattern of workforce adjustments at the former Allergan campus after earlier reductions. The operational context is notable because the Allergan eye-care franchise has been navigating product life-cycle and regulatory developments, including a recent FDA complete response letter related to a fast-acting follow-on targeting the Botox franchise. The latest cuts reinforce that R&D and commercial resource allocation remains a near-term lever for large pharma units under pressure.